Chiodo L A, Bunney B S
J Neurosci. 1983 Aug;3(8):1607-19. doi: 10.1523/JNEUROSCI.03-08-01607.1983.
Extracellular single unit recording techniques were used to study the effects of both acute and repeated oral neuroleptic administration on the in vivo activity of rat A9 and A10 dopaminergic (DA) neurons. All antipsychotic drugs examined acutely (haloperidol, l-sulpiride, chlorpromazine, and clozapine) increased the number of spontaneously firing DA neurons in both A9 and A10 compared to controls. Repeated (21 day) treatment with haloperidol, l-sulpiride, and chlorpromazine (antipsychotic drugs which can cause extrapyramidal side effects) markedly reduced the number of active DA cells below control levels in both regions. The "silent" DA neurons were in an apparent state of tonic depolarization inactivation since they could be induced to discharge by the microiontophoretic application of the inhibitory neurotransmitter gamma-aminobutyric acid, but not the excitatory amino acid glutamate. The depolarization inactivation observed may be specific for antipsychotic drugs since a non-neuroleptic phenothiazine (promethazine), the inactive isomer of sulpiride (d-sulpiride), and a tricyclic antidepressant (desmethylimipramine) neither increased DA activity when given acutely nor induced depolarization inactivation when administered repeatedly. In contrast to the other drugs tested, repeated treatment with clozapine (an effective antipsychotic drug which does not produce extrapyramidal side effects) resulted in the depolarization inactivation of A10 neurons but not A9 cells. These data suggest that neuroleptics which can induce extrapyramidal side effects produce depolarization inactivation of both A9 and A10 neurons whereas antipsychotic drugs which lack this property inactivate only A10 neurons. It is suggested that the time-dependent development of A9 DA neuron inactivation induced by repeated neuroleptic treatment may provide a mechanism for understanding the delayed onset of extrapyramidal side effects often observed with these drugs.
采用细胞外单单位记录技术,研究急性和反复口服抗精神病药物对大鼠A9和A10多巴胺能(DA)神经元体内活性的影响。与对照组相比,所有急性给予的抗精神病药物(氟哌啶醇、左旋舒必利、氯丙嗪和氯氮平)均增加了A9和A10中自发放电DA神经元的数量。用氟哌啶醇、左旋舒必利和氯丙嗪(可引起锥体外系副作用的抗精神病药物)进行反复(21天)治疗后,两个区域中活跃DA细胞的数量明显低于对照水平。“沉默”的DA神经元处于明显的紧张性去极化失活状态,因为它们可通过微量离子电泳施加抑制性神经递质γ-氨基丁酸而被诱导放电,但不能被兴奋性氨基酸谷氨酸诱导放电。观察到的去极化失活可能对抗精神病药物具有特异性,因为非抗精神病吩噻嗪(异丙嗪)、舒必利的无活性异构体(右旋舒必利)和三环类抗抑郁药(去甲丙咪嗪)在急性给药时既不增加DA活性,反复给药时也不诱导去极化失活。与其他测试药物相反,用氯氮平(一种有效的抗精神病药物,不产生锥体外系副作用)反复治疗导致A10神经元去极化失活,但A9细胞未出现这种情况。这些数据表明,可诱导锥体外系副作用的抗精神病药物会使A9和A10神经元均发生去极化失活,而缺乏此特性的抗精神病药物仅使A10神经元失活。有人提出,反复使用抗精神病药物诱导的A9 DA神经元失活的时间依赖性发展,可能为理解这些药物常观察到的锥体外系副作用延迟发作提供一种机制。